Trial Profile

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 2/3 Study to Evaluate the Efficacy and Safety of TVP-1012 at 0.5 mg or 1 mg in Levodopa Treated Parkinson's Disease Patients With Wearing Off

Status: Completed

Phase of Trial: Phase II/III

Latest Information Update: 28 Feb 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

25 Feb 2022 Planned End Date changed from 1 Sep 2016 to 17 Sep 2016.
16 Sep 2020 Results of post-hoc analysis of clinical trials (NCT02337725, NCT02337738) presented at the 24th International Congress of Parkinson's Disease and Movement Disorders
29 Jun 2017 According to a Takeda Pharma media release, based on the data from CCT-001 and CCT-002 studies the company has submitted a New Drug Application (NDA) to the Ministry of Health, Labour and Welfare in Japan for rasagiline mesylate for the treatment of Parkinson's disease.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com